Mitazalimab
First-line metastatic pancreatic ductal adenocarcinoma (PDAC)
Key Facts
About Alligator Bioscience
Alligator Bioscience is a publicly traded biotech developing tumor-directed antibody therapies to combat cancer by activating the immune system directly within the tumor. Its lead candidate, the CD40 agonist mitazalimab, is preparing for Phase 3 development in first-line metastatic pancreatic cancer following highly encouraging Phase 2 results with a 24-month survival benefit. The company's strategy leverages a specialized antibody platform to create localized immunotherapies, aiming to overcome immune suppression in solid tumors while managing systemic toxicity. Recent corporate milestones include an R&D Day in August 2025 and the publication of its 2025 Annual Report.
View full company profileAbout alligator-bioscience-ab
Alligator Bioscience is a clinical-stage biotech focused on developing tumor-directed antibody therapies for cancer. Its core strategy is built on proprietary platforms like ALiCE® and RUBY™ to generate highly specific, next-generation immuno-oncology drugs. The company's most advanced program, mitazalimab (a CD40 agonist), is in a pivotal Phase 2/3 trial for metastatic pancreatic ductal adenocarcinoma (PDAC), representing a significant near-term value inflection point. Alligator operates as an R&D-centric organization, advancing its pipeline through internal development and strategic partnerships.
View full company profile